Citi Pharma (KAR:CPHL) Pretax Margin %: % (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨75.08
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Pretax Margin %?

Citi Pharma KAR:CPHL +0.37% 15 Pretax Margin % is % as of . 20. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 961 Drug Manufacturers companies, Citi Pharma ranks worse than 104058.17% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Citi Pharma's Pre-Tax Income for the six months ended in . 20 was ₨0.00 Mil. Citi Pharma's Revenue for the six months ended in . 20 was ₨0.00 Mil. Therefore, Citi Pharma's pretax margin for the quarter that ended in . 20 was %.

The historical rank and industry rank for Citi Pharma's Pretax Margin % or its related term are showing as below:


KAR:CPHL's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.28
* Ranked among companies with meaningful Pretax Margin % only.

Citi Pharma  (KAR:CPHL) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Citi Pharma Pretax Margin % Related Terms

Citi Pharma Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Citi Pharma's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Pretax Margin % Chart

Citi Pharma Annual Data
Trend
Pretax Margin %

Citi Pharma Semi-Annual Data
Pretax Margin %

KAR:CPHL vs ZTS, UTHR, VTRS: Pretax Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citi Pharma Pretax Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Citi Pharma's Pretax Margin % falls into.


KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Citi Pharma's Pretax Margin for the fiscal year that ended in . 20 is calculated as

Pretax Margin=Pre-Tax Income (A: . 20 )/Revenue (A: . 20 )
=/
= %

Citi Pharma's Pretax Margin for the quarter that ended in . 20 is calculated as

Pretax Margin=Pre-Tax Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Citi Pharma (KAR:CPHL) has a Pretax Margin % of % as of . 20. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Citi Pharma and its competitors. According to the industry distribution chart, Citi Pharma ranks #999999 out of 961 companies in the Drug Manufacturers industry.
Is Citi Pharma's Pretax Margin % too high?
Citi Pharma's current Pretax Margin % is %. Based on the distribution chart, Citi Pharma ranks #999999 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Citi Pharma ranks #999999 out of 961 companies for Pretax Margin %. This places Citi Pharma in the lower half of its industry. The industry median Pretax Margin % is 7.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Citi Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citi Pharma's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current Pretax Margin % of %. The current Pretax Margin % is %. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current Pretax Margin % is % as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨75.08
Price